Sanofi Fined $53M In France Over Generic Plavix Smears

Law360, New York (May 14, 2013, 1:27 PM EDT) -- France’s antitrust regulator has fined Sanofi SA €40.6 million ($52.7 million) after ruling the drugmaker had engaged in a campaign to discourage doctors and pharmacists from prescribing or substituting generic versions of its former blockbuster blood thinner Plavix, the watchdog announced Tuesday.

According to the French Competition Authority, Sanofi had abused its dominant position in the market to engage in a “strategy of denigration” against generic Plavix competitors between September 2009 and January 2010, in an attempt to limit the entry of those competitors into the...
To view the full article, register now.